When Anxiety Turns Into Depression: A Guide for Founders and Executives Who Used to Be the Strong One

High performers have a specific relationship with anxiety. A certain amount of it is fuel. It sharpens a pitch, keeps a deal on track, and pushes through the last week before a launch. For years, it works.

Then, for some people, it stops working and starts working against them. Anxiety that used to be situational becomes constant. Panic attacks appear, recede, and return. Sleep breaks. Medication gets tried and either does nothing or makes things worse. And somewhere in that stretch, the anxiety converts into depression: the loss of joy, the fear of things that used to be pleasures, the sense of mourning a self that seems to have vanished.

This guide explains that progression, why it hits founders and executives in a recognizable pattern, what the treatment options are, and what the most advanced option looks like from first call to final session.

The barrel model. Stress accumulates like water in a barrel. High performers keep the level just below the rim for years by draining it through achievement and momentum. When something raises the level, the overflow isn't stress. It's the underlying vulnerability that was managed, not treated.

Identity built on capability. When self-worth depends on being the decisive one, impairment in the decision-making circuitry is doubly destabilizing. The person loses the function and the identity at once.

High-functioning masking. Executives are skilled at performing competence while deteriorating. Clinicians treat conservatively because the patient looks fine. Partial improvement gets accepted as success.

Self-imposed pressure. The expectations others hold are usually lower than the ones the person holds for themselves. There is no external pressure to reduce, because the pressure is internal.

Antidepressants adjust brain chemistry, and for a majority of people that's sufficient. But they take four to eight weeks to reach full effect, they can flatten emotion before they improve mood, and in some individuals, particularly early in treatment, they intensify anxiety or produce bleak mornings that are worse than the baseline.

If a medication makes you feel less like yourself rather than more, that is clinically important. Report it to your prescriber immediately. Do not stop on your own, and do not assume you're obligated to push through. If a medication produces any thoughts of self-harm, contact your prescriber the same day.

If you've had one or more adequate medication trials without adequate relief, you meet the definition for treatment-resistant depression, and you qualify for evaluation for circuitry-based treatment. You don't need to have failed five medications first.

SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy) was developed at Stanford's Brain Stimulation Lab by psychiatrists and neuroscientists studying why depression fails to respond to medication. Their published trials established the protocol; Magnus Medical, a California-based medical technology company, licensed it and built the SAINT Neuromodulation System that delivers it in clinical practice. The system received FDA Breakthrough Device Designation and was cleared in 2022 for adults with major depressive disorder who haven't gotten adequate relief from antidepressants in their current episode.

Magnus Medical doesn't treat patients directly. It designates clinics that have the required equipment, training, and quality standards as Verified SAINT Providers, and publishes its clinical data, provider directory, and patient resources at magnusmedical.com. Neuro Wellness TMS Centers of America is a Verified SAINT Provider.

On the depression. The primary target. In trials, most participants reached remission within the treatment week, with the average at day two to three. Patients commonly describe the shift as the fog lifting, energy returning, and the ability to think clearly again, rather than simply feeling less sad.

On the anxiety and anticipatory dread. SAINT is cleared for major depressive disorder, not for anxiety disorders as a standalone diagnosis. But because the targeted circuit regulates both mood and the threat response, patients treated for depression commonly report that anxiety, panic, and avoidance ease as the depression lifts. The dinners, the travel, the speaking roles stop registering as threats. Clinically, depression is what's treated; the anxiety typically follows.

On the physical symptoms. Head pressure, headaches, gastrointestinal disruption, and exhaustion that are driven by the depression tend to improve with it. Symptoms with a separate medical cause need their own evaluation.

On medication. SAINT doesn't require stopping anything, and nothing enters the bloodstream, so there's no interaction. Many patients do eventually simplify their regimen, but only after treatment and only with their prescriber, over time.

What it doesn't do. It doesn't guarantee remission; roughly one in five trial participants didn't reach it. It doesn't remove the stressors that filled the barrel; those still need managing, and the daily therapy check-ins during treatment are partly about that. And it isn't appropriate for everyone: non-removable metal near the head, seizure history, and implanted devices are exclusions screened at consultation.

Insurance coverage for SAINT varies by plan; some cover it with prior authorization, others do not yet. Self-pay is available. Coverage is checked before anything is scheduled, and the care team explains the options in advance.

From first call to completed treatment can be under two weeks when schedules allow. For patients with a specific deadline — a family event, a board meeting, a commitment they don't want to face at half capacity — the care team can often structure the intake, imaging, and treatment week around it.